{
    "clinical_study": {
        "@rank": "129423", 
        "arm_group": [
            {
                "arm_group_label": "PRGF-Endoret", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Saline Solution", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in\n           both men and women and is caused by the action of androgens in genetically predisposed\n           individuals.\n\n        -  This clinical trial was designed to evaluate the efficacy and safety of using a\n           preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment\n           of androgenetic alopecia."
        }, 
        "brief_title": "Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia", 
        "condition": "Androgenetic Alopecia", 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Androgenetic alopecia according to the following scales:\n\n          -  Men: Hamilton/Norwood Scale: grades II-VI\n\n          -  Women: Ludwig Scale grades I-II.\n\n          -  Possibility of follow-up during the study\n\n        Exclusion Criteria:\n\n          -  No androgenetic alopecia\n\n          -  Telogen and anagen effluvium\n\n          -  Active inflammation or infection in the intervention area\n\n          -  Presence of active systemic infections.\n\n          -  Background of cancerous or precancerous lesions.\n\n          -  Background of connective or rheumatic diseases.\n\n          -  Suffering from any serious blood disorders.\n\n          -  To have undergone treatments for alopecia in the previous 6 months.\n\n          -  Previous hair implants\n\n          -  Intake of drugs that affect hair loss.\n\n          -  Be undergoing immunosuppressive therapy and/or anticoagulants.\n\n          -  Known intolerance to mesotherapy.\n\n          -  Taking contraceptives containing cyproterone acetate.\n\n          -  Pregnancy\n\n          -  In general, any limitations that would prevent the proper application of both\n             treatments and the right monitoring of the efficacy variables."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885676", 
            "org_study_id": "BTI-01D-EC/12/ALO"
        }, 
        "intervention": [
            {
                "arm_group_label": "PRGF-Endoret", 
                "description": "PRGF-Endoret mesotherapy micro injection.", 
                "intervention_name": "PRGF-Endoret", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Saline Solution", 
                "description": "Saline Solution mesotherapy micro injection", 
                "intervention_name": "Saline Solution", 
                "intervention_type": "Other"
            }
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Eduardo Anitua, Medical Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Spain", 
                        "state": "Alava", 
                        "zip": "01007"
                    }, 
                    "name": "Cl\u00ednica Eduardo Anitua."
                }, 
                "investigator": {
                    "last_name": "Juli\u00e1n Bay\u00f3n, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alopecia.ccdermatologico@gmail.com", 
                    "last_name": "Rogelia Navarro, Medical Doctor", 
                    "phone": "965 14 04 60"
                }, 
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain", 
                        "zip": "03014"
                    }, 
                    "name": "Centro dermatol\u00f3gico est\u00e9tico"
                }, 
                "investigator": {
                    "last_name": "Rogelia Navarro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.", 
        "overall_contact": {
            "email": "eduardoanitua@eduardoanitua.com", 
            "last_name": "Eduardo Anitua, MD, DDS, PhD", 
            "phone": "+34 945160650"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hair density (number of hairs per cm2) will be measured for each treatment group", 
            "measure": "Change from baseline in Hair density at three months (number of hairs per cm2)", 
            "safety_issue": "No", 
            "time_frame": "3 months post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885676"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hair width will be measured for each treatment group", 
                "measure": "Hair Width (micrometers)", 
                "safety_issue": "No", 
                "time_frame": "Basal, 1, 2, and 3 months post-treatment"
            }, 
            {
                "description": "Hair cycle has different phases.  Two of the most important are anagen (active growth phase of hair follicles) and telogen (resting phase of the hair follicle). This secondary outcome measure allows to measure the efficacy of the PRGF-Endoret treatment.", 
                "measure": "Anagen/telogen ratio", 
                "safety_issue": "No", 
                "time_frame": "Basal, 1, 2, and 3 months post-treatment"
            }, 
            {
                "description": "Terminal hair density will be established for each one of the treatments", 
                "measure": "Terminal Hair Density", 
                "safety_issue": "No", 
                "time_frame": "Before each one of the treatments and 1, 2 and 3 months post-treatment."
            }, 
            {
                "description": "Vellous hair will be measured for each treatment group", 
                "measure": "Vellous hair density", 
                "safety_issue": "No", 
                "time_frame": "Basal,1, 2 and 3 months post-treatment"
            }
        ], 
        "source": "Biotechnology Institute IMASD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biotechnology Institute IMASD", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}